Higher vascularity at infiltrated peripheral edema differentiates proneural glioblastoma subtype

BACKGROUND AND PURPOSE Genetic classifications are crucial for understanding the heterogeneity of glioblastoma. Recently, MR perfusion imaging techniques have demonstrated their ability to determine molecular alterations. In this work, we investigated whether perfusion markers within infiltrated peripheral edema were associated with proneural, mesenchymal, classical and neural subtypes. MATERIALS AND METHODS ONCOhabitats open web service was used to obtain the cerebral blood volume at the infiltrated peripheral edema for MRI studies of 50 glioblastoma patients from The Cancer Imaging Archive: TCGA-GBM. ANOVA and Kruskal-Wallis tests were carried out in order to assess the association between vascular features and the subtypes. For assessing specific differences, Mann-Whitney U-test was conducted. Finally, the association of overall survival with molecular and vascular features was assessed using univariate and multivariate Cox models. RESULTS ANOVA and Kruskal-Wallis tests for the maximum cerebral blood volume at the infiltrated peripheral edema between the four subclasses yielded false discovery rate corrected p-values of <0.001 and 0.02, respectively. This vascular feature was significantly higher (p=0.0043) in proneural patients compared to the rest of the subtypes while conducting Mann-Whitney U-test. The multivariate Cox model pointed to redundant information provided by vascular features at the peripheral edema and proneural subtype when analyzing overall survival. CONCLUSIONS Higher relative cerebral blood volume at infiltrated peripheral edema is associated with proneural glioblastoma subtype suggesting underlying vascular behavior related to molecular composition in that area.

[1]  Elies Fuster-García,et al.  Non-local spatially varying finite mixture models for image segmentation , 2021, Statistics and Computing.

[2]  Carlos Sáez,et al.  Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study , 2020, Journal of magnetic resonance imaging : JMRI.

[3]  Elies Fuster-García,et al.  ONCOhabitats Glioma Segmentation Model , 2019, BrainLes@MICCAI.

[4]  Juan Miguel García-Gómez,et al.  ONCOhabitats: A system for glioblastoma heterogeneity assessment through MRI , 2019, Int. J. Medical Informatics.

[5]  L. Cerchia,et al.  Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma , 2019, International journal of molecular sciences.

[6]  G. Finocchiaro,et al.  The landscape of the mesenchymal signature in brain tumours , 2019, Brain : a journal of neurology.

[7]  U. Klose,et al.  In Vivo Molecular Profiling of Human Glioma , 2019, Clinical Neuroradiology.

[8]  Luis Martí-Bonmatí,et al.  Improving the estimation of prognosis for glioblastoma patients by MR based hemodynamic tissue signatures , 2018, NMR in biomedicine.

[9]  Mary Goldman,et al.  The UCSC Xena platform for public and private cancer genomics data visualization and interpretation , 2018, bioRxiv.

[10]  A. Bozzao,et al.  Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI , 2018, Journal of Neuro-Oncology.

[11]  Luis Martí-Bonmatí,et al.  Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival. , 2018, Radiology.

[12]  Songhua Zhan,et al.  Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI , 2017, Journal of magnetic resonance imaging : JMRI.

[13]  Gang Wang,et al.  Diffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumors , 2016, Radiation Oncology.

[14]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[15]  Yu Yao,et al.  Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas , 2016, Medicine.

[16]  M. McLean,et al.  Multimodal MRI can identify perfusion and metabolic changes in the invasive margin of glioblastomas , 2015, Journal of magnetic resonance imaging : JMRI.

[17]  A. Vortmeyer,et al.  Integrated genomic characterization of IDH1-mutant glioma malignant progression , 2015, Nature Genetics.

[18]  X. Bian,et al.  Lower MGMT expression predicts better prognosis in proneural-like glioblastoma. , 2015, International journal of clinical and experimental medicine.

[19]  R. Bourgon,et al.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  José V. Manjón,et al.  Automated Glioblastoma Segmentation Based on a Multiparametric Structured Unsupervised Classification , 2015, PloS one.

[21]  Peter Canoll,et al.  MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma , 2014, Proceedings of the National Academy of Sciences.

[22]  Scott N. Hwang,et al.  Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. , 2014, Radiology.

[23]  K. Aldape,et al.  Using the molecular classification of glioblastoma to inform personalized treatment , 2014, The Journal of pathology.

[24]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[25]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[26]  S. Choi,et al.  Cerebral Blood Volume Calculated by Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging: Preliminary Correlation Study with Glioblastoma Genetic Profiles , 2013, PloS one.

[27]  Benjamin M Ellingson,et al.  Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. , 2013, Neuro-oncology.

[28]  David Gutman,et al.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.

[29]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[30]  T. Cloughesy,et al.  Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma , 2012, American Journal of Neuroradiology.

[31]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[32]  F. Jolesz,et al.  Correction: Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2012, PLoS ONE.

[33]  J. Uhm IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[34]  Ferenc A. Jolesz,et al.  Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.

[35]  Joel H. Saltz,et al.  The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas , 2010, PloS one.

[36]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[37]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[38]  Ru-Fang Yeh,et al.  Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. , 2010, Radiology.

[39]  R. Arceci Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma , 2010 .

[40]  A. Falini,et al.  Tumours , 2008, Neurological Sciences.

[41]  T. Hirai,et al.  Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study , 2008, American Journal of Neuroradiology.

[42]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[43]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[44]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[45]  R M Weisskoff,et al.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.

[46]  A. Norman,et al.  in patients with , 1995 .